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Aims Stroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In
COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first occurrence of death, stroke, or
myocardial infarction compared with placebo in patients with HFrEF, coronary artery disease (CAD), and sinus
rhythm. We now examine the incidence, timing, type, severity, and predictors of stroke or a transient ischaemic at-
tack (TIA), and seek to establish the net clinical benefit of treatment with low-dose rivaroxaban.
...................................................................................................................................................................................................
Methods
and results
In this double-blind, randomized trial, 5022 patients who had HFrEF(<_40%), elevated natriuretic peptides, CAD,
and who were in sinus rhythm were treated with rivaroxaban 2.5 mg b.i.d. or placebo in addition to antiplatelet
therapy, after an episode of worsening HF. The primary neurological outcome for this post hoc analysis was time
to first event of any stroke or TIA. Over a median follow-up of 20.5 (25th–75th percentiles 20.0–20.9) months,
150 all-cause stroke (127) or TIA (23) events occurred (ischaemic stroke in 82% and haemorrhagic stroke in
11% of stroke events). Overall, 47.5% of first-time strokes were either disabling (16.5%) or fatal (31%). Prior
stroke, low body mass index, geographic region, and the CHA2DS2-VASc score were predictors of stroke/TIA.
Rivaroxaban significantly reduced the primary neurological endpoint of all-cause stroke or TIA compared with
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placebo by 32% (1.29 events vs. 1.90 events per 100 patient-years), adjusted for the time from index HF event
to randomization and stratified by geographic region (adjusted hazard ratio 0.68, 95% confidence interval 0.49–
0.94), with a number needed to treat of 164 patients per year to prevent one stroke/TIA event. The principal
safety endpoint of fatal bleeding or bleeding into a critical space, occurred at a similar rate on rivaroxaban and
placebo (0.44 events vs. 0.55 events per 100 patient-years).
...................................................................................................................................................................................................
Conclusions Patients with HFrEF and CAD are at risk for stroke or TIA in the period following an episode of worsening heart
failure in the absence of atrial fibrillation. Most strokes are of ischaemic origin and nearly half are either disabling or
fatal. Rivaroxaban at a dose of 2.5 mg b.i.d. reduced rates of stroke or TIA compared with placebo in this population.
...................................................................................................................................................................................................
Trial
Registration
COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death,
Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an
Episode of Decompensated Heart Failure); ClinicalTrials.gov NCT01877915.
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Introduction
Stroke is a devastating occurrence in patients with heart failure with
reduced ejection (HFrEF).1,2 The sequelae of stroke include a marked
decline in health-related quality of life, higher healthcare utilization,
and increased cost of care.3 Although atrial fibrillation (AF) has been
the traditional target population for stroke risk reduction, patients
with HF and sinus rhythm face elevated risk of stroke compared with
the general population.4,5 Important gaps exist in our contemporary
understanding of stroke risk in this unique population, since prior
studies used historical information, relied on administrative claims
data, and did not include patients on current guideline-mandated
medical therapies.6
Since stroke as an endpoint has been challenging to study or safely
modify in HFrEF and sinus rhythm,7–10 contemporary guidelines do
not support a routine strategy of anticoagulation in patients with
HFrEF in the absence of AF or other compelling indication.11,12 Non-
vitamin K antagonist oral anticoagulants (NOACs) are approved for
use in patients with AF or in the treatment or prevention of venous
thromboembolism. COMMANDER HF (A Study to Assess the
Effectiveness and Safety of Rivaroxaban in Reducing the Risk of
Death, Myocardial Infarction, or Stroke in Participants with Heart
Failure and Coronary Artery Disease Following an Episode of
Decompensated Heart Failure) did not demonstrate significant re-
duction in the composite primary endpoint of death, myocardial in-
farction, or stroke with addition of rivaroxaban at a dose of 2.5 mg
b.i.d. compared with placebo in patients with HFrEF, coronary artery
disease (CAD), and sinus rhythm receiving antiplatelet therapy and
standard HF therapy.13 However, rivaroxaban did appear to reduce
risk of stroke (a component of the primary endpoint).13
In this post hoc analysis of COMMANDER HF, among patients
after a recent episode of worsening chronic HFrEF, sinus rhythm,
and CAD, we set out to comprehensively explore (i) the inci-
dence, timing, type, and severity of stroke or a transient ischaemic
attack (TIA); (ii) clinical predictors of the occurrence of stroke or
TIA; and (iii) the net clinical benefit of treatment with low-dose
rivaroxaban compared with placebo on prevention of stroke
or TIA.
Methods
COMMANDER HF trial
The design14 and primary findings13 of COMMANDER HF have been
previously described. In brief, COMMANDER HF was a global, multi-
centre, double-blind, randomized clinical trial that evaluated the safety
and efficacy of rivaroxaban compared with placebo among patients with
chronic HFrEF (<_40%) with recent episode of worsening HF within
21 days and underlying CAD. Participants were randomized 1:1 to re-
ceive low-dose rivaroxaban 2.5 mg b.i.d. or matching placebo, in addition
to standard care at the discretion of the treating physician. Subjects that
had prior stroke within 90 days of randomization were excluded. The
COMMANDER HF study protocol was approved by the ethics commit-
tees/institutional review boards of each participating site and all partici-
pants provided written informed consent for participation. The study
complied with the Declaration of Helsinki.
Stroke, transient ischaemic attack, and
safety
Study visits occurred at 4 weeks, 12 weeks, and every 12 weeks thereafter
to determine safety and efficacy endpoints. Investigators determined key
events using dedicated case report forms based on explicit event defini-
tions and criteria. Available source documentation was reviewed by the
local trial monitor and transmitted to the sponsor for independent con-
firmatory review using protocol-specified criteria (Supplementary mater-
ial online, Table S1).
The primary neurological outcome for the present post hoc analysis is
time to first all-cause stroke or TIA, defined as new, sudden, focal
neurological deficit resulting from a presumed cerebrovascular cause
without another identifiable cause after the study randomization. If
neurological deficits lasted longer than 24 h, a stroke definition was
met; if it lasted less than 24 h, a TIA was diagnosed. Strokes were fur-
ther categorized based on available imaging as ischaemic, haemor-
rhagic, subarachnoid, or uncertain. A Modified Rankin Scale (mRS), a
validated metric to determine stroke-related disability that categorizes
stroke severity on a scale of 0–6 with higher scores denoting more dis-
ability (mRS 0–5) and ultimately death (mRS 6),15 was obtained be-
tween 6 and 18 weeks following a first or recurrent stroke or at the
end of study, whichever occurred first.
The principal safety outcome was fatal bleeding or bleeding into a critical
space with a potential for causing permanent disability, which was also a
2 M.R. Mehra et al.
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site-adjudicated event. Risk of events is described using incidence rates
(events per 100 patient-years of observation).
Statistical analysis
All patients included in the intention-to-treat analytic set (randomized
participants with signed valid informed consent) were assessed in this
post hoc analysis of stroke or TIA events which were characterized by tim-
ing, type, and severity. The timing of stroke/TIA was calculated by adding
the time from worsening HF episode (index event) to randomization, to
the time from randomization to incident stroke/TIA during follow-up, or
until the global trial end date (GTED). The time-course of stroke risk was
described from the time of the index episode of worsening HF only in the
placebo arm. The incremental incidence rate and its 95% confidence
interval for each time segment were derived using the bootstrap method
(10 000 resamples) and Kaplan–Meier cumulative risk estimates.
Baseline clinical profiles of those experiencing any stroke/TIA during
the follow-up duration (up-to-GTED) were compared with patients who
were free from stroke/TIA during the study. Given significant treatment
effects of rivaroxaban, a risk prediction model for the stroke or TIA event
was built among patients in the placebo arm alone. Pre-specified varia-
bles5,16 which were tested in stroke or TIA prediction models included:
age, geographic region, race, body mass index, New York Heart
Association classification, timing from episode of worsening HFrEF, prior
stroke, hypertension, diabetes mellitus, and ejection fraction. Univariate
and multivariate analyses were performed. Final model discrimination
was determined using the concordance statistic (C-statistic). We quanti-
fied optimism in model estimates of C-statistics using a bootstrap resam-
pling approach. Optimism estimates, averaged across 100 bootstrap
samples, were subtracted from the naı¨ve estimate of model discrimin-
ation. The percentile-corrected interval of the C-statistic was calculated
by subtracting the 2.5 and 97.5 percentiles of optimism estimates from
the naı¨ve estimates.
To account for death as a competing risk event, the similar model selec-
tion process was repeated using a covariate-adjusted proportional sub-
distribution hazard model (Fine and Gray17) to identify key independent
predictors of stroke or TIA. This competing risk regression model identified
similar predictors as the Cox proportional hazards model, and as such the
latter approach is presented for simplicity. An established score for AF
(CHA2DS2-VASc) was also assessed in risk prediction of stroke/TIA.
The overall treatment effects were determined by Cox proportional haz-
ards models, accounting for time from index HF event to randomization as a
covariate and stratified by geographic region. We performed interaction anal-
yses to determine if the efficacy and safety of rivaroxaban was modified by
baseline dual antiplatelet therapy or the CHA2DS2-VASc score.
Incidence rates of first stroke or TIA across treatment arms were esti-
mated using Kaplan–Meier analyses. Incidence rates of each subtype of
stroke and TIA were described by treatment arm. Given the post hoc na-
ture of this analysis and focus on an individual component of the primary
composite endpoint of COMMANDER HF, treatment effects were fur-
ther adjusted for key selected covariates (as described above).
The principle safety outcomes were assessed using a similar Cox pro-
portional hazards models without adjusting for time from index HF event
to randomization for the on-treatment period, defined as the observation
period from the first dose of the study drug to 2 days after the last dose
of the study drug.
The number needed to treat (NNT) to prevent 1 primary neurological
outcome (first all-cause stroke or TIA) and the number needed to harm
(NNH) to cause 1 principal safety outcome (fatal bleeding or bleeding into
a critical space with a potential for causing permanent disability) were calcu-
lated from the rates of absolute risk reduction using annualized incidence
rates. The NNT and NNH were also calculated for subgroups above and
below the median (closest integer) CHA2DS2-VASc risk score.
Two-sided P-values with significance threshold of P< 0.05 were con-
sidered statistically significant, and no multiplicity adjustments were made
in this post-hoc analysis. All computations were performed using SAS
version 9.4.
Results
From September 2013 to October 2017, 5022 patients were
enrolled in COMMANDER HF from 628 sites across 32 countries.
All patients were included in this post hoc analysis. Overall, 2507
patients were randomly assigned to rivaroxaban and 2515 to placebo.
COMMANDER HF participants were on average 66.4 years of age,
22.9% women, and 82.2% White. Overall, 40.9% had a history of dia-
betes mellitus. Over 90% were treated with aspirin at baseline and a
third were on dual antiplatelet therapy. At baseline, use of back-
ground guideline-directed medical therapy for HFrEF was high.
Phenotyping stroke/transient ischaemic
attack after an episode of worsening
chronic heart failure with reduced
ejection
Over a median follow-up of 20.5 (25th–75th percentiles 20.0–20.9)
months, 150 stroke or TIA events occurred; 5 (3.3%) occurred within
30 days and 24 (16.0%) occurred within 90 days and 49 (32.7%) by
6 months of index hospitalization. The risk of stroke/TIA calculated
only in the placebo arm after an episode of worsening HFrEF
remained elevated well beyond 6 months (Figure 1). Of these, 127
were first stroke events and 23 were first TIA events. Ischaemic
stroke accounted for 82% of stroke events. There was limited
observed heterogeneity in baseline characteristics among patients
who did and did not experience a stroke/TIA during follow-up
(Table 1). CHA2DS2-VASc scores were higher among patients who
experienced a stroke/TIA in follow-up (median 5; 25th–75th percen-
tiles 4–6) compared with those who did not (median 4; 25th–75th
percentile: 3–5); Figure 2.
Stroke severity and subsequent adverse
events
Stroke severity as assessed using the mRS (score 0–6) among 133
patients included 31% fatal events (mRS 6), 16.5% with moderate-to-
severe disability (mRS 3–5), while 51.1% were non-disabling events
(mRS 0–2). Patients surviving after a stroke or TIA event faced risks
of mortality of 26% (33 out of 126), recurrent stroke or TIA of 7% (9
out of 126), and rehospitalization for HF of 21% (26 out of 126) dur-
ing study follow-up.
Predicting stroke or transient ischaemic
attack after an episode of worsening
chronic heart failure with reduced
ejection
In a multivariate model among placebo-treated patients when clinical-
ly relevant variables were simultaneously tested, only prior history of
stroke, low body mass index, and region were independently
Rivaroxaban and stroke in worsening heart failure 3
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.predictive of stroke/TIA after worsening HFrEF. Patients in Latin
America, Western Europe, and South Africa independently carried
the highest risks of stroke or TIA. Optimism-corrected C-statistic of
this model with selected clinically relevant variables was 0.70 (per-
centile corrected interval 0.65–0.74) (Table 2). Per point, the
CHA2DS2-VASc was significantly associated with risk of first stroke/
TIA [hazard ratio (HR) 1.29; 95% CI 1.13–1.48; P< 0.001] among
placebo-treated patients; the score displayed modest discrimination
(C-statistic 0.62).
Treatment effects of rivaroxaban on
occurrence of first and recurrent stroke/
transient ischaemic attack and safety
events
In this post hoc analysis, rivaroxaban significantly reduced the primary
neurological endpoint of all-cause stroke or TIA compared with pla-
cebo by 32% (2.4% vs. 3.5%; 1.29 events vs. 1.90 events per 100
patient-years; HR 0.68; 95% CI 0.49–0.94; P= 0.02); Take home figure.
Known stroke subtype events (including haemorrhagic stroke) and
TIA all directionally favoured rivaroxaban vs. placebo, however, only
ischaemic stroke was significantly reduced by rivaroxaban vs. placebo
by 36% (0.86 events vs. 1.34 events per 100 patient-years; HR 0.64;
95% CI 0.43–0.95; P= 0.028); Table 3. Consistent reductions were
observed for all-cause stroke alone and the composite of ischaemic
stroke or TIA. Fatal or moderate-severely disabling strokes, defined
by mRS 3–6, were lower with rivaroxaban compared with placebo
(39.6% vs. 52.5%). After adjusting for clinically relevant covariates
(Table 2), rivaroxaban retained significant and independent risk re-
duction of stroke/TIA (HR 0.68; 95% CI 0.49–0.94). During follow-
up, a total of nine recurrent stroke or TIA events occurred (two in
the rivaroxaban arm and seven in the placebo arm).
Overall, we estimate that 164 patients per year would need to be
treated with rivaroxaban to prevent 1 stroke or TIA event. The effi-
cacy and safety of rivaroxaban vs. placebo did not differ by back-
ground dual antiplatelet therapy or the CHA2DS2-VASc risk score
with cut-off at the median integer (4); all interaction P-values >0.30.
Among patients with CHA2DS2-VASc <_4, rivaroxaban reduced
stroke/TIA from 2.8% to 2.2% (HR 0.78; 95% CI 0.49–1.25) with an
NNT of 316 patient-years. Among patients with CHA2DS2-VASc
above 4, rivaroxaban reduced stroke/TIA from 4.5% to 2.7% (HR
0.59; 95% CI 0.37–0.92) with an NNT of 96 patient-years (Table 4).
The principal safety endpoint, fatal bleeding, or bleeding into a crit-
ical space with potential for permanent disability, occurred at a similar
rate in rivaroxaban-treated patients compared with placebo-treated
patients (0.44 events vs. 0.55 events per 100 patient-years). As bleed-
ing events were directionally lower in the rivaroxaban arm with re-
spect to the principal safety endpoint, there was no signal of net harm
observed (Table 4).
Discussion
In this post hoc analysis of a large, global, randomized placebo-
controlled clinical trial, we found that patients recently treated for an
episode of worsening HF in sinus rhythm face a risk of stroke (1.6 per
100 patient-years) approaching rates observed among patients with
chronic HF and AF (2.0 per 100 patient-years).4 Ischaemic strokes
are the first such event in 82% of patients. This risk is noted to in-
crease early immediately following the index episode of worsening
HF, peaks by 6-months and persists throughout the period of obser-
vation. Nearly half of all first stroke events are either fatal or disabling
and those individuals that survive these events continue to face risk
of major adverse cardiovascular events, including death. The history
Figure 1 Temporal pattern of risk of stroke/transient ischaemic attack after an episode of worsening chronic heart failure with reduced ejection in
the placebo arm of COMMANDER HF. The total duration of time was calculated by adding the time from worsening heart failure episode to ran-
domization to the time from randomization to stroke/transient ischaemic attack. The incremental incidence rate (red bars)) and its 95% confidence
intervals (grey lines) for each time segment were derived using the bootstrap method (10 000 resamples). Kaplan–Meier cumulative risk estimates
over the first 12 months after an episode of worsening heart failure are displayed in blue.
4 M.R. Mehra et al.
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.of a prior stroke, low body mass index, and geographic region repre-
sent important independent predictors of such events. The addition
of rivaroxaban 2.5 mg b.i.d. to background antiplatelet therapy mark-
edly reduces risk of first stroke or TIA compared with placebo by
32%, when adjusted for clinically relevant covariates. The reduced
risk of stroke among rivaroxaban-treated patients after worsening
HFrEF in COMMANDER HF mirrors rates observed among studies
of stable chronic HFrEF in sinus rhythm4 and translates into a NNT
of 164 per year, a number that is considerably improved when apply-
ing the CHA2DS2-VASc score of >4, with a NNT of 96 per year.
Rivaroxaban at a low dose is associated with a safe and acceptable
bleeding profile; we did not observe between-arm differences in fatal
or critical space bleeding (the principal safety endpoint), haemor-
rhagic stroke, or death. Rivaroxaban did increase bleeding when
compared with placebo using secondary measures of safety end-
points as reported in the primary publication of the COMMANDER
HF trial.13
Early clinical trials that tested the usefulness of vitamin K antago-
nists compared with antiplatelet therapy or no antithrombotic ther-
apy in HFrEF were relatively small, underpowered, and did not
demonstrate a clear net clinical benefit in stroke reduction.7–9 In
the larger Warfarin vs. Aspirin in Reduced Cardiac Ejection
Fraction (WARCEF) trial of 2306 patients with chronic HFrEF in
sinus rhythm, warfarin did not influence the primary endpoint of is-
chaemic stroke, intracerebral haemorrhage, or death compared
with aspirin. However, warfarin did significantly reduce ischaemic
stroke at the expense of increased major haemorrhage as com-
pared with aspirin.10 COMMANDER HF evaluated rivaroxaban at a
low-dose and safely reduced stroke or TIA, but did not modify the
primary endpoint of the trial which was a composite of death, myo-
cardial infraction, or stroke. This was largely because the lower inci-
dence of a first stroke event was overwhelmed by a high
proportional occurrence of HF deaths as the principal event.
However, our findings on the stroke reduction signal in this unique
population that suffered a recent episode of worsening HF are also
supported by prospective trials evaluating extended-duration
therapy with a factor Xa inhibitor, betrixaban, among patients hos-
pitalized for medical illness.18,19 Low-dose rivaroxaban, which at
this dose decreases thrombin generation,20 may attenuate residual
thrombotic risk early and late following worsening HFrEF18 and
among patients with stable atherosclerotic vascular disease21 or
after acute coronary syndromes.22
Step-wise pharmacological and device developments over the last
3 decades have modified disease progression in HFrEF and led to lon-
gitudinal declines in sudden death.23 Despite this therapeutic success
(primarily targeting neurohormonal pathways attenuating adverse
myocardial remodelling), patients face residual thrombotic risks.
Stroke, a most feared morbidity related to HF, remains a significant
problem even among patients in sinus rhythm, across an ejection frac-
tion spectrum.24 Although these events appear to occur at a relatively
low frequency, we found that nearly half of index stroke events were
fatal or disabling, highlighting the important lasting morbidity associ-
ated with this complication. Importantly, the analysis of this trial indi-
cates that the early period after worsening HFrEF is ‘vulnerable’ with
a large proportion of events occurring during that phase and accumu-
lating thereafter with a peak within 6 months; however, there is no
period when the risk is completely attenuated. Few data exist in this
particular time period and even those that do evaluate such early
post-discharge outcomes, do not provide long-term follow-up.18,19
A recent exploratory analysis of COMMANDER HF assessed the
utility of rivaroxaban in modifying composite thromboembolic com-
plications (inclusive of myocardial infarction, ischaemic stroke, sudden
unwitnessed death, or symptomatic venous thromboembolism).25
Taken together with our study, these data highlight that patients after
an episode of worsening HF face a broad range of residual thrombot-
ic risks, of which stroke represents a critical modifiable event.
As patients presenting with worsening HFrEF have widely hetero-
geneous patient profiles, application of a clinical risk score may
identify subpopulations that may particularly benefit from thrombo-
prophylaxis. Few clinical risk scores have been validated to improve
risk prediction to guide stroke prevention in HFrEF and sinus
rhythm.26 The CHA2DS2-VASc score has been a validated and widely
Figure 2 Distribution of COMMANDER HF participants and observed stroke or transient ischaemic attack rates by CHA2DS2-VASc score.
* Given strong treatment effect of rivaroxaban vs. placebo on stroke/transient ischaemic attack, Cox proportional hazards models for risk prediction
were performed in the placebo group alone.
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.applied risk prediction tool among patients with AF, and in our ana-
lysis appears to be an important predictor of stroke outcomes among
patients in sinus rhythm.4,27 This risk prediction score was significant-
ly associated with first-time stroke or TIA, but its performance as a
continuous variable was modest. This may reflect relatively low event
rates, high observed competing risks of death and rehospitalization
for worsening HF in this high-risk population,25 and lack of accounting
of specific metrics of HF severity and status. In aggregate, we estimate
that 164 patients per year would need to be treated with low-dose
rivaroxaban to prevent 1 stroke or TIA event. If the CHA2DS2-VASc
score is applied using a cut-point of 4 (the median score of our
population), the NNT would reduce to 96 per year. Thus, a risk
score targeted approach to cautious implementation of this prevent-
ive therapy may warrant further investigation in patients deemed at
high risk for stroke in HF and without AF. Given the regional hetero-
geneity in event profiles consistent with prior observations across
global HF programs,28,29 risk scores may need to be adapted
accounting for local populations.
Study limitations
This is a post hoc analysis which used an endpoint that lacked formal
independent adjudication by a clinical events committee and instead
....................................................................................................................................................................................................................
Table 2 Risk predictors of stroke or transient ischaemic attack in final prediction model
Wald statistics v2 Hazard ratio (HR) P-value
Region 14.49 0.006
Asia Pacific vs. Eastern Europe 1.45 (0.41–5.15)
Western Europe & South Africa vs. Eastern Europe 2.97 (1.59–5.57)
North America vs. Eastern Europe 1.74 (0.56–5.37)
Latin America vs. Eastern Europe 2.54 (1.23–5.23)
History of prior stroke 10.09 2.35 (1.39–3.98) 0.002
Body mass index (kg/m2) 3.87 0.95 (0.91–1.00) 0.049
History of hypertension 3.01 1.67 (0.94–2.99) 0.083
Age (per year) 1.39 1.01 (0.99–1.04) 0.239
Time from index episode of worsening heart failure to randomization (per day) 0.58 1.01 (0.99–1.03) 0.448
Left ventricular ejection fraction (per %) 0.51 0.99 (0.96–1.02) 0.473
New York Heart Association class 0.34 0.952
Class I vs. Class IV
Class II vs. Class IV 1.38 (0.33–5.85)
Class III vs. Class IV 1.49 (0.35–6.37)
History of diabetes mellitus 0.23 1.11 (0.71–1.74) 0.633
White race 0.10 1.19 (0.40–3.49) 0.754
Optimism-corrected C-statistic (percentile-correct interval) 0.70 (0.65–0.74)
No events occurred in the placebo arm of New York Heart Association Class I patients, so a hazard ratio was not estimable.
....................................................... .......................................................
....................................................................................................................................................................................................................
Table 3 Effects of rivaroxaban vs. placebo on stroke or transient ischaemic attack
Rivaroxaban Placebo
n/N (%) Incidence rate per
100 patient-years
n/N (%) Incidence rate per
100 patient-years
HR (95% CI) P-value
Primary neurological endpoint:
all-cause stroke or TIA
61/2507 (2.43) 1.29 89/2515 (3.54) 1.9 0.68 (0.49, 0.94) 0.02
All-cause stroke 51/2507 (2.03) 1.08 76/2515 (3.02) 1.62 0.67 (0.47, 0.95) 0.025
Ischaemic stroke 41/2507 (1.64) 0.86 63/2515 (2.50) 1.34 0.64 (0.43, 0.95) 0.028
Haemorrhagic stroke 6/2507 (0.24) 0.13 8/2515 (0.32) 0.17 0.74 (0.25, 2.13) 0.572
Subarachnoid haemorrhage 1/2507 (0.04) 0.02 3/2515 (0.12) 0.06 0.33 (0.03, 3.16) 0.334
Uncertain type of stroke 4/2507 (0.16) 0.08 2/2515 (0.08) 0.04 2.01 (0.37, 10.99) 0.420
TIA 10/2507 (0.40) 0.21 13/2515 (0.52) 0.27 0.77 (0.34, 1.75) 0.525
Ischaemic stroke or TIA 51/2507 (2.03) 1.08 76/2515 (3.02) 1.62 0.66 (0.46, 0.95) 0.023
Cox proportional hazards models were used to determine hazard ratios (HR) and 95% confidence intervals, adjusted for time from index heart failure event to randomization
and stratified by region.
TIA, transient ischaemic attack.
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.relied on site investigator-based event adjudication. However, as
stroke was a component of the primary composite endpoint, data
collection to support site adjudication was carefully performed. As
imaging was not uniformly available to exclude cerebral infarction
among patients presenting with transient neurological symptoms, we
specifically focused on the composite of stroke or TIA as the primary
neurological outcome. Patients with a history of stroke within 90
days of randomization were excluded which may lead to underesti-
mation of stroke risk in this population. Given the exploratory nature
of this analysis, treatment effects were adjusted for clinically relevant
Take home figure Time to first occurrence of stroke or transient ischaemic attack. Cox proportional hazards models were adjusted for all
covariates presented in Table 2. Analyses were performed in the intention-to-treat cohort including all randomized unique subjects who have a signed
valid informed consent. CI, confidence interval; HR, hazard ratio; TIA, transient ischaemic attack.
............................................... ...............................................
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
................................................. .................................................
....................................................................................................................................................................................................................
Table 4: Application of the CHA2DS2-VASc risk score with cut-off at the median score of 4 to the COMMANDER HF
trial
Rivaroxaban Placebo
n/N (%) Incidence
rate (per 100
patient-years)
n/N (%) Incidence
rate (per 100
patient-years)
NNT
patient-years
HR (95% CI) P-value
Primary neurological endpoint: all-cause stroke or TIA
COMMANDER HF
cohort
61/2507 (2.4%) 1.29 89/2515 (3.5%) 1.90 164 0.68 (0.49–0.94) 0.02
CHA2DS2-VASc <_ 4 31/1412 (2.2%) 1.13 40/1424 (2.8%) 1.44 316 0.79 (0.49–1.26) 0.382
b
CHA2DS2-VASc > 4 30/1095 (2.7%) 1.52 49/1091 (4.5%) 2.56 96 0.59 (0.37–0.93)
Rivaroxaban Placebo
n/N (%) Incidence
rate (per 100
patient-years)
n/N (%) Incidence
rate (per 100
patient-years)
NNH
patient-yearsa
HR (95% CI) P-value
Principal safety endpoint: fatal bleeding or bleeding into a critical space
COMMANDER HF
cohort
18/2499 (0.7%) 0.44 23/2509 (0.9%) 0.55 – 0.81 (0.44–1.49) 0.491
CHA2DS2-VASc <_ 4 8/1406 (0.6%) 0.33 13/1422 (0.9%) 0.53 – 0.65 (0.27–1.56) 0.495
b
CHA2DS2-VASc > 4 10/1093 (0.9%) 0.60 10/1087 (0.9%) 0.60 – 1.00 (0.42–2.40)
Cox proportional hazards models were used to determine hazard ratios (HR) and 95% confidence intervals (CI), adjusted for time from index heart failure event to randomiza-
tion and stratified by region. Number needed to treat (NNT) or number needed to harm (NNH) was calculated based on the difference in incidence rates per 100 patient-year
between the treatment groups.
TIA, transient ischaemic attack.
aAs the principal safety endpoint occurred at a higher incidence rate in the placebo arm compared with rivaroxaban arm in the overall COMMANDER HF trial and by
CHA2DS2-VASc subgroups, NNH was not calculated.
bInteraction P-value.
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covariates (which did not modify the direction, magnitude, or
significance of the results). These data should be considered explora-
tory, hypothesis-generating and require prospective validation, espe-
cially since rivaroxaban has not received regulatory approval for use
for the indication of stroke prevention in patients with worsening
HFrEF in the absence of other reasons for anticoagulation (such
as AF).
Conclusions
In this exploratory analysis of a large, global, randomized clinical trial
of patients with recently worsening HFrEF, CAD, and sinus rhythm,
an ischaemic stroke was most often observed as the first stroke event
and was frequently disabling or fatal. The addition of low-dose rivar-
oxaban appeared to safely attenuate risk of stroke or TIA in the vul-
nerable early and late phase after a recent episode of worsening
HFrEF. Within the context of the relatively low absolute risk of
stroke/TIA events, our data suggest that selected at-risk populations
of patients with HFrEF and sinus rhythm may be identified using trad-
itional risk scores and further investigation of such targeted
approaches are warranted.
Supplementary material
Supplementary material is available at European Heart Journal online.
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